Cargando…

Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages

Resistance to drugs used to treat tuberculosis disease (TB) continues to remain a public health burden, with missense point mutations in the underlying Mycobacterium tuberculosis bacteria described for nearly all anti-TB drugs. The post-genomics era along with advances in computational and structura...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunstall, Tanushree, Phelan, Jody, Eccleston, Charlotte, Clark, Taane G., Furnham, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372558/
https://www.ncbi.nlm.nih.gov/pubmed/34422898
http://dx.doi.org/10.3389/fmolb.2021.619403
_version_ 1783739817993961472
author Tunstall, Tanushree
Phelan, Jody
Eccleston, Charlotte
Clark, Taane G.
Furnham, Nicholas
author_facet Tunstall, Tanushree
Phelan, Jody
Eccleston, Charlotte
Clark, Taane G.
Furnham, Nicholas
author_sort Tunstall, Tanushree
collection PubMed
description Resistance to drugs used to treat tuberculosis disease (TB) continues to remain a public health burden, with missense point mutations in the underlying Mycobacterium tuberculosis bacteria described for nearly all anti-TB drugs. The post-genomics era along with advances in computational and structural biology provide opportunities to understand the interrelationships between the genetic basis and the structural consequences of M. tuberculosis mutations linked to drug resistance. Pyrazinamide (PZA) is a crucial first line antibiotic currently used in TB treatment regimens. The mutational promiscuity exhibited by the pncA gene (target for PZA) necessitates computational approaches to investigate the genetic and structural basis for PZA resistance development. We analysed 424 missense point mutations linked to PZA resistance derived from ∼35K M. tuberculosis clinical isolates sourced globally, which comprised the four main M. tuberculosis lineages (Lineage 1–4). Mutations were annotated to reflect their association with PZA resistance. Genomic measures (minor allele frequency and odds ratio), structural features (surface area, residue depth and hydrophobicity) and biophysical effects (change in stability and ligand affinity) of point mutations on pncA protein stability and ligand affinity were assessed. Missense point mutations within pncA were distributed throughout the gene, with the majority (>80%) of mutations with a destabilising effect on protomer stability and on ligand affinity. Active site residues involved in PZA binding were associated with multiple point mutations highlighting mutational diversity due to selection pressures at these functionally important sites. There were weak associations between genomic measures and biophysical effect of mutations. However, mutations associated with PZA resistance showed statistically significant differences between structural features (surface area and residue depth), but not hydrophobicity score for mutational sites. Most interestingly M. tuberculosis lineage 1 (ancient lineage) exhibited a distinct protein stability profile for mutations associated with PZA resistance, compared to modern lineages.
format Online
Article
Text
id pubmed-8372558
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83725582021-08-19 Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages Tunstall, Tanushree Phelan, Jody Eccleston, Charlotte Clark, Taane G. Furnham, Nicholas Front Mol Biosci Molecular Biosciences Resistance to drugs used to treat tuberculosis disease (TB) continues to remain a public health burden, with missense point mutations in the underlying Mycobacterium tuberculosis bacteria described for nearly all anti-TB drugs. The post-genomics era along with advances in computational and structural biology provide opportunities to understand the interrelationships between the genetic basis and the structural consequences of M. tuberculosis mutations linked to drug resistance. Pyrazinamide (PZA) is a crucial first line antibiotic currently used in TB treatment regimens. The mutational promiscuity exhibited by the pncA gene (target for PZA) necessitates computational approaches to investigate the genetic and structural basis for PZA resistance development. We analysed 424 missense point mutations linked to PZA resistance derived from ∼35K M. tuberculosis clinical isolates sourced globally, which comprised the four main M. tuberculosis lineages (Lineage 1–4). Mutations were annotated to reflect their association with PZA resistance. Genomic measures (minor allele frequency and odds ratio), structural features (surface area, residue depth and hydrophobicity) and biophysical effects (change in stability and ligand affinity) of point mutations on pncA protein stability and ligand affinity were assessed. Missense point mutations within pncA were distributed throughout the gene, with the majority (>80%) of mutations with a destabilising effect on protomer stability and on ligand affinity. Active site residues involved in PZA binding were associated with multiple point mutations highlighting mutational diversity due to selection pressures at these functionally important sites. There were weak associations between genomic measures and biophysical effect of mutations. However, mutations associated with PZA resistance showed statistically significant differences between structural features (surface area and residue depth), but not hydrophobicity score for mutational sites. Most interestingly M. tuberculosis lineage 1 (ancient lineage) exhibited a distinct protein stability profile for mutations associated with PZA resistance, compared to modern lineages. Frontiers Media S.A. 2021-07-23 /pmc/articles/PMC8372558/ /pubmed/34422898 http://dx.doi.org/10.3389/fmolb.2021.619403 Text en Copyright © 2021 Tunstall, Phelan, Eccleston, Clark and Furnham. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Tunstall, Tanushree
Phelan, Jody
Eccleston, Charlotte
Clark, Taane G.
Furnham, Nicholas
Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages
title Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages
title_full Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages
title_fullStr Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages
title_full_unstemmed Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages
title_short Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages
title_sort structural and genomic insights into pyrazinamide resistance in mycobacterium tuberculosis underlie differences between ancient and modern lineages
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372558/
https://www.ncbi.nlm.nih.gov/pubmed/34422898
http://dx.doi.org/10.3389/fmolb.2021.619403
work_keys_str_mv AT tunstalltanushree structuralandgenomicinsightsintopyrazinamideresistanceinmycobacteriumtuberculosisunderliedifferencesbetweenancientandmodernlineages
AT phelanjody structuralandgenomicinsightsintopyrazinamideresistanceinmycobacteriumtuberculosisunderliedifferencesbetweenancientandmodernlineages
AT ecclestoncharlotte structuralandgenomicinsightsintopyrazinamideresistanceinmycobacteriumtuberculosisunderliedifferencesbetweenancientandmodernlineages
AT clarktaaneg structuralandgenomicinsightsintopyrazinamideresistanceinmycobacteriumtuberculosisunderliedifferencesbetweenancientandmodernlineages
AT furnhamnicholas structuralandgenomicinsightsintopyrazinamideresistanceinmycobacteriumtuberculosisunderliedifferencesbetweenancientandmodernlineages